Background: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with recurrent highgrade glioma (HGG) after failure of surgery, radiation therapy, and chemotherapy.
introduction
Mutation and/or gene amplification of the epidermal growth factor receptor (EGFR) or Her2/neu gene (both members of the EGFR family of transmembrane tyrosine kinase receptors) is frequently found in human epithelial cancer cells [1, 2] . These acquired genetic alterations lead to hyperactivity of EGFRregulated intracellular signaling pathways among which are the phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinases (MAPK) pathway. This results in an increase in cancer cell motility, invasion, and proliferation as well as an inhibition of apoptosis and induction of angiogenesis [1] .
EGFR signaling can be inhibited with targeted monoclonal antibodies (mAbs) (e.g. cetuximab and panitumumab) or small-molecule tyrosine kinase inhibitors (smTKIs) [2] . mAbs have demonstrated activity in KRAS wild-type colorectal cancer, head and neck squamous cell carcinoma and non-small-cell lung cancer (NSCLC) [2, 3] . Across different tumor types, an increased EGFR gene copy number has been correlated with sensitivity to EGFR-targeted treatment and sensitivity to the Her2/neu-targeted mAb trastuzumab is strictly correlated with an increased gene copy number [4] [5] [6] . Activity of smTKIs is associated with the presence of specific point mutations within the ATP pocket of the EGFR as found in a small subgroup of patients with NSCLC [7, 8] .
Patients with recurrent high-grade glioma (HGG) following prior surgery, radiation therapy (RT) and alkylating chemotherapy have a poor prognosis (median survivals are 39 and 30 weeks for patients with grade III and grade IV glioma, respectively) and no controlled trial has demonstrated to improve survival [9] . Among all cancers, an increased copy number of the EGFR gene has been observed most frequently in glioblastoma and anaplastic astrocytoma. Most often these amplified sequences are present in a very high copy number on 'double minute chromosomes' and they contain mutated EGFR sequences with the constitutively activated extracellular domain deletion mutant EGFRvIII being the most common [10, 11] .
The EGFR gene copy number may vary substantially in individual cells of a glioma with EGFR-amplified cells, but the presence of the EGFRvIII mutant has been demonstrated in glioma stem cells [12] . The EGFRvIII mutant defines anaplastic astrocytoma with a worse prognosis and a clinically distinct subtype of glioblastoma [13] [14] [15] [16] ; in addition, high EGFR expression is an independent prognostic factor in newly diagnosed patients with glioblastoma treated with RT and temozolomide [17] . Therefore, EGFR represents a particularly attractive molecular target in patients with recurrent HGG.
Disappointing results were obtained with the EGFR inhibitors erlotinib and gefitinib throughout a number of phase II clinical trials in patients with recurrent glioblastoma or newly diagnosed glioblastoma [18] [19] [20] [21] [22] . Only a small subpopulation experienced durable disease control. However, interpreting these results one needs to consider the absence of activating mutations within the tyrosine kinase domain of EGFR in HGG and the uncertainty regarding the extent of EGFR inhibition in glioma tissues [23, 24] . Although a number of molecular markers (including phosphatase and tensin homology (PTEN), EGFRvIII and phosphorylated Akt) have been suggested to predict sensitivity, these observations have not been reproduced across studies and therefore remain of uncertain value today [19, 22, 25, 26] .
The use of an mAb in the treatment of recurrent glioma seems counterintuitive because these large molecules do not readily cross an intact blood-brain barrier. Preclinical models, however, support the use of cetuximab (ErbituxÒ, Merck KGaA, Darmstadt, Germany), a chimeric IgG1 mAb that binds to EGFR with high specificity and affinity, as an active antiglioma agent and cetuximab is more efficient in inhibiting the EGFRvIII mutant as compared with the smallmolecule EGFR inhibitors [27] [28] [29] . Phase I studies with a nonhumanized anti-EGFR mAb demonstrated the presence of mAb within resected glioma tissues [30, 31] , and the EGFRtargeted mAb nimotuzumab and CD20-targeted mAb rituximab have demonstrated therapeutic activity against pediatric pontine glioma and primary central nervous system lymphoma, respectively [32] [33] [34] [35] . Recently, patients with recurrent HGG responding to cetuximab treatment have been reported [36] .
We hypothesized that the amplification status of the EGFR gene in HGG might determine the sensitivity to cetuximab, an IgG1 chimeric mAb directed against the EGFR, and therefore conducted a phase II clinical trial in which patients were stratified at baseline according to the amplification status of the EGFR gene determined by FISH (EGFR FISH).
patients and methods study entry criteria and EGFR FISH
To be eligible, patients had to have histological documentation of supratentorial World Health Organization (WHO) grade III or IV glioma. In addition, determination of the EGFR gene copy number of the glioma cells by FISH in a single reference laboratory (UZ Brussel) was required. EGFR FISH results were classified according to published criteria [37] . This analysis was carried out on archival formalin-fixed, paraffin-embedded glioma tissue blocks using a commercially available kit (LSI EGFR/CEP 7 Dual Color Probe, Abbott Laboratories, Abbott Park, IL) according to the manufacturer's instructions. Histologic diagnosis was confirmed by central pathology review carried out by AM.
Patients were required to have demonstrated evidence of progressive disease (PD) on magnetic resonance imaging (MRI) of the brain following prior surgery, RT and chemotherapy (including temozolomide), a Karnofsky performance status (KPS) of ‡60% at study entry, and an absolute neutrophil count of 1500 cells/mm 3 , a platelet count of 100 000 cells/mm 3 , a white blood cell count of 3500 cells/mm 3 , and a hemoglobin level of 9 g/dl. The total serum bilirubin level was required to be 1.5· the upper limit of normal and the alkaline phosphatase and aspartate aminotransferase/alanine aminotransferase levels were required to be 5· the upper limit of normal. The serum creatinine level was required to be <1.5· the upper limit of normal. Patients were required to have recovered from toxic effects of prior surgery, RT, and chemotherapy and may not have had either RT or a systemic drug therapy within 4 weeks of initiating cetuximab. Patients were required to be on a stable dose of corticosteroids for at least 2 weeks before initiating cetuximab.
This protocol was reviewed and approved by the institutional review board of each participating center, and all patients gave written informed consent before participation.
treatment plan
All patients received an initial dose of cetuximab 400 mg/m 2 administered i.v. during 120 min followed by weekly doses of cetuximab at 250 mg/m 2 during 60 min. Patients received premedication before the administration of cetuximab consisting of 10 mg oral cetirizine (or a similar oral antihistamine). Treatment was continued until disease progression, unacceptable toxicity or patient's refusal. Gadolinium-enhanced MRI of the brain and response assessments (based on Macdonald criteria for response evaluation in central nervous system glioma) were carried out at least every 8 weeks [38] . In the event of a grade 3 adverse event (AE), the dose of cetuximab was withheld until recovery to grade £2 or for a maximum of 2 weeks and resumed thereafter at the prior dose. For a second grade 3 event, cetuximab was reduced one dose level, and for a third event, cetuximab was reduced two dose levels (first to 200 mg/m 2 , then to 150 mg/ m 2 ). In the event of a hypersensitivity reaction of grade 1 or 2, the cetuximab infusion was stopped and the patient was treated as appropriate. The infusion could be resumed at 50% of the previous rate once the event resolved or decreased to grade 1 in severity. If a second hypersensitivity reaction was experienced, treatment was stopped and the patient was removed from the study. For a grade 3 or 4 hypersensitivity reaction, the patient was treated as appropriate and taken off study with no additional cetuximab treatment.
study design and statistical analysis
This was an open-label, nonrandomized, stratified, two-stage, phase II trial conducted at seven different Belgian medical centers. The primary objective of this study was to determine the tumor response rate for single-agent cetuximab separately in patients with EGFR gene-amplified and -nonamplified glioblastoma. We therefore conducted a stratified, two-arm, phase II, open-label, nonrandomized study according to a Simon's twostage Minimax design (alfa 0.05 and beta 0.2), with separate decision rules for EGFR gene-amplified and -nonamplified patients. An accrual of response-assessable patients per subgroup was calculated for a total of 2 · 27 patients on the study. For each subgroup, 13 response-assessable patients were to be accrued to the first stage. If no responses were observed in that subgroup, no additional patients would be accrued, and it would be concluded that the true response rate is unlikely to be 5% for that subgroup. Otherwise, if at least one response was seen in the subgroup, accrual to that subgroup would continue to the second stage (total 27 patients). If at least four responses were seen in a subgroup, we would conclude that cetuximab has sufficient activity for further study in this setting.
Secondary objectives were to determine the time to tumor progression (TTP), progression-free survival (PFS; from the date of recruitment to documented progression or death), and overall survival (OS) and safety within each subgroup and for the overall population. Demographic and baseline laboratory results were summarized using descriptive statistics for all treated patients. An exact two-sided 95% Clopper-Pearson confidence interval (CI) was computed for each response rate. For the survival and time to progression, Kaplan-Meier estimates were calculated; and 6-month survival percentages and medians with two-sided 95% CIs are reported. Worst toxicity grades (using National Cancer Institute-Common Toxicity Criteria, Version 3.0) per patient were tabulated for selected AEs and laboratory measurements. Table 1 .
The patient study population with EGFR gene amplification on average was older (median 50 versus 57 years); more patients were diagnosed with de novo glioblastoma (79% versus 63%), had received upfront combination of radiation and temozolomide (86% versus 63%), and were recruited at first recurrence (57% versus 22%) as opposed to patients with nonamplified EGFR status who were more often treated at second or subsequent recurrences.
duration of treatment and dose intensity of cetuximab
At the time of this analysis (1 May 2008), a total of 815 cetuximab administrations were carried out. The median number of administrations per patient was 9 (range 2-86 administrations; only two patients received less than four administrations). Only two patients required one dose reduction of cetuximab (to 200 mg/m 2 weekly) because of treatment-limiting skin toxicity. The primary reason for discontinuing treatment was disease progression (48 patients). efficacy response rate. All patients who received any cetuximab on this trial were considered assessable for efficacy. Of the 55 patients treated, three obtained a partial response (PR) and 17 patients obtained a stable disease (SD) for a disease control rate (PR + SD) of 36% [95% exact CI 23% to 49%; based on investigator assessments]. As shown in Table 2 , disease control rate was numerically superior in patients with EGFR gene amplification but the difference did not reach statistical significance. The extent of tumor regression was not clearly 
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Annals of Oncology correlated with the duration of disease control as all three patients who obtained a PR experienced PD within 4 months from the initiation of cetuximab (Figures 1 and 2 ). An improvement or stabilization of disease-related symptoms was observed in patients experiencing disease control (investigator assessment). Patients with an initial diagnosis of low-grade glioma or anaplastic glioma without EGFR amplification seemed to benefit less as compared with patients with de novo glioblastoma or anaplastic astrocytoma with EGFR amplification (2 of 10 versus 18 of 45 patients experienced disease control).
median time to progression, PFS, and OS. The median TTP was 1.9 months (95% exact CI 1.6-2.2 months) and the 6-month PFS percentage was 7.3% (95% exact CI 0% to 14%). The median OS from time of initiation of protocol therapy for the 55 treated patients was 5.0 months (95% exact CI 4.2-5.9 months) and the 6month survival percentage was 37.9% (95% exact CI 25% to 90%). As demonstrated in Table 3 and Figure 3 , PFS and OS were numerically superior in patients with EGFR gene amplification but this difference did not reach statistical difference. Five patients had a PFS of >9 months on cetuximab treatment. 
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In an exploratory univariate analysis, patients who experienced grade 2 or 3 skin toxicity had a significantly better PFS and OS [median PFS was 1.7 months (95% CI 1.4-2.0) versus 2.9 months (95% CI 2.8-3.0) (log-rank P = 0.009) and the median OS was 4.6 months (95% CI 3.8-5.5) versus 9.7 months (95% CI 6.2-13.2) (log-rank P = 0.012) for patients who did not versus patients who did experience grade 2 or 3 skin toxicity, respectively]. No significant correlation was found between survival and age, KPS, initial WHO differentiation grade, gender, or the number of recurrences before the patient received cetuximab.
safety Treatment was generally well tolerated and there were no grade 4 treatment-related AEs. Treatment-related toxicity data for all patients (n = 55) are summarized in Table 4 .
Skin toxicity was the most frequently observed AE. Six patients (11%) developed an acne-like rash (folliculitis/ original article Annals of Oncology dermitis; grade 2 in four patients and grade 3 in two patients) that typically affected the face, scalp, and upper trunk. The intensity of this toxicity typically decreased when treatment was continued beyond 8 weeks and tended to fluctuate thereafter. Other skin toxic effects consisted of xerodermia (dry skin with exfoliation), paronichia (inflammation of the nail wall), fissures at the hands and/or feet, dermatitis of the eyelids, and increased facial hair growth. These side-effects were more often observed with prolonged treatment. Three patients (5%) developed a subacute transient decrease in their consciousness that necessitated hospitalization within 24 h from their first cetuximab administration. All recovered within a few days and cetuximab could be readministered without repetition of the AE.
Hematologic toxicity was absent except for grade 2 or 3 thrombocytopenia which was observed in 10% of the patients.
One patient experienced intratumoral hemorrhage (in the absence of thrombocytopenia or impaired coagulation) that was associated with a partial tumor response in the third week of treatment.
discussion
The results of this multi-institutional phase II trial indicate that cetuximab has a low single-agent activity in patients with recurrent HGG following surgery, RT, and chemotherapy. Two patterns of antitumor activity were observed. About 20%-30% of patients experienced disease control, with rapid regression of contrast-enhancing lesions in some, that was not sustained >5 months and seemingly did not translate into a marked improvement of survival. Additionally, a small percentage (5 of 55 patients, 9%) experienced a durable disease control ( ‡9 months) and improved OS as compared with the rest of the study population.
Of the five patients (9%) who had an outstanding favorable clinical evolution (PFS of ‡9 months), all except one had been diagnosed with radiological and clinical PD at >6 months after the administration of RT. It is therefore unlikely that they were diagnosed with pseudoprogression and therefore are considered to be true responders to cetuximab. The outcome of this small subgroup of patients might resemble the glioblastoma patients reported to derive a sustained benefit from the small-molecule EGFR inhibitors gefitinib or erlotinib [26] . No correlation was found in these five patients with the histology, WHO grade, or EGFR amplification status. We have attempted to characterize all tumors for additional molecular-genetic markers reported to correlate with the sensitivity to EGFR blockade in other studies (including EGFRvIII and PTEN). The accuracy and reproducibility of these immunohistochemical assays in our hands was, however, far below that of EGFR FISH and no reliable results could be obtained.
An improvement or stabilization of disease-related symptoms was observed in patients who experienced disease control. Patients with an EGFR-amplified glioma more frequently experienced disease control as opposed to patients 
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without EGFR amplification (42.9 versus 29.6%) suggesting a correlation between the EGFR copy number and sensitivity to cetuximab. This difference, however, was not statistically significant and there was also an imbalance in baseline prognostic factors between both groups (the EGFR-amplified group consisted of more patients with 'de novo glioblastoma', diagnosed at an older age, who were treated more frequently with combination radiotherapy and temozolomide upfront and received cetuximab more often at first recurrence because of progression during or early after administration of upfront combination therapy, but more patients in this group had a baseline KPS of >70%). Treatment was generally well tolerated. The only frequent treatment-related toxicity was at the level of the skin. We observed the same correlation between the severity of the skin toxicity and survival as has been described in many other studies with cetuximab.
The median survival of our patient population was dismal and is illustrative of the aggressive nature of recurrent HGG that progresses despite surgery, radiation, and temozolomide chemotherapy. Although the disease control rate we observed was short lived in most patients, one needs to bear in mind the poor natural prognosis for these patients. The tumor response rate observed in this study is comparable to what has been observed with cetuximab as a single agent in the treatment of patients with previously treated NSCLC and the observed disease control rate (tumor response plus SD) with that observed in unselected patients with previously treated colorectal cancer [39] [40] [41] . Given the synergistic effect of EGFR inhibition with cetuximab and RT, further investigation of cetuximab in the upfront combination treatment of patients with newly diagnosed glioblastoma might be rewarding [18] . Early results of an ongoing phase II study on this combination for patients with newly diagnosed glioblastoma have been reported recently [42] .
Recent insights into the biology of HGG revealed that multiple receptor tyrosine kinases are coactivated in these cancer cells and, in addition, a number of tumor suppressor genes such as the PTEN, p53, and p19 are lost [43] [44] [45] [46] . Inhibitors targeting molecules within the PI3K pathway that themselves are not mutated, such as the mammalian target of rapamycin inhibitor temsirolimus, have been reported to have a variable activity across studies. Combination with EGFR-targeted agents is under investigation [47] [48] [49] . Proto-oncogenes that act within the PI3K-and MAPK-signaling pathways are involved by activating mutations including PIK3CA, MET, NRAS, and BRAF [50] [51] [52] [53] . In analogy to the resistance to EGFR inhibitors observed in KRAS mutant colorectal and NSCLC, each of these mutations might be able to mediate resistance to EGFR inhibition in HGG. Evidence that the MET oncogene can mediate resistance to EGFR inhibition has recently been forwarded [43, 54] . Specific inhibitors targeting these oncogenes are under early clinical investigation. Besides EGFR, the frequency of mutation of these additional proto-oncogenes has been rather low and rational combination of targeted agents in glioblastoma might require individual genetic profiling, an objective that might become possible with the development of high-throughput genetic analysis [55] [56] [57] [58] .
funding Stichting tegen Kanker, Fonds Wetenschappelijk Onderzoek Vlaanderen, and Willy Gepts Wetenschappelijk Fonds UZ Brussel.
acknowledgements
We would like to acknowledge the patients who consented to participate in this study and their families and the company of Merck/Serono for the provision of cetuximab study medication and a grant to cover the patient insurance. We also like to thank the data managers of the participating centers and especially Katrien Van den Bossche (UZ Brussel) for the data collection and analysis and Soetkin Vlassak and Iris Carton (Merck/ Serono) for their support to this study and critical review of the manuscript.
references
